Betting big on the Chinese market, Dr. Reddy’s Laboratories has started outsourcing manufacture of some of the drugs to local partners. The company which won the tender to market Olanzapine drug in China, is expected to launch it beginning next year.
The company is working towards filing and an eventual launch of over 70 products, across the chosen therapy areas, over the next few years. It has 8-10 products currently available in the market. All company’s products are marketed either through its Joint Venture, Kushnan Rotam Reddy Pharmaceuticals (KRRP) or through its partners in China. The products are manufactured either in the plant owned by KRRP in China, or partners in China, or in India by Dr. Reddy's.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1850.40 |
| Dr. Reddys Lab | 1310.50 |
| Cipla | 1365.25 |
| Zydus Lifesciences | 939.10 |
| Lupin | 2442.35 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: